Sepsis Pipeline Could Be Resuscitated With Narrower Trials, Researchers Propose
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sepsis trials designed with narrower enrollment criteria could allow treatment effects to emerge, countering the “signal to noise” problem that has plagued late-stage trials in sepsis, researchers suggest.
You may also be interested in...
The Long Goodbye: Lilly Finally Kicks Troubled Sepsis Drug Xigris To The Curb
Eli Lilly & Co. announced Oct. 25 that it is ending its ten-year relationship with Xigris, withdrawing the sepsis drug from all markets and ceasing further clinical trials.
Knoll Considering Segard Plans; Sepsis Study Shows Small Mortality Benefit
Knoll is considering the next step for its TNF inhibitor Segard, after one of two pivotal trials for sepsis showed a modest mortality benefit.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.